← Leaderboards
Benjamin T Kopp
Emory University
$3,476,580
Attributed
$6,129,864
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2015–25$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,129,864 · 5
By mechanism
R01$4,839,161 · 3
K08$831,624 · 1
R21$459,079 · 1
Top collaborators
- Amal O Amer4 shared
- Luanne Hall-Stoodley4 shared
- Santiago Partida-Sanchez4 shared
- Susan Creary3 shared
- Darryl Brice Hood3 shared
- Asuncion Mejias3 shared
- Octavio Ramilo2 shared
- Matthew Z Anderson1 shared
Most similar at Emory University
Same institution · by research overlap
- Eric J Sorscher$13,371,665
- Sandra B. Dunbar$10,524,522
- Rabindra Marie-Jean Tirouvanziam$4,658,925
- Darryl Brice Hood$3,153,688
- Susan Creary$2,068,115
Others in their field
Top investigators on “Chronic”
- Judith S. Currier · University Of California Los Angeles$245,012,139
- Lawrence Corey · Fred Hutchinson Cancer Center$209,947,290
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$201,828,077
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$173,476,538
- John M Lachin · George Washington University$125,152,883
- David M Nathan · Massachusetts Institute Of Technology$120,438,756
Research focus
ChronicSignal TransductionImmune ResponseInflammationPublic HealthPathogenCystic FibrosisResponseMediatingAntibioticsReactive Oxygen SpeciesLifeAutophagocytosisProductionCystic Fibrosis PatientsInfectionBacteriaMacrophageLungImmune SystemInnovationPathway InteractionsMissionImmune
Grant awards (17)
SMILE (Sickle Cell Disease Microbiologic and Immunologic Links to Health)$794,661
R01 · FY2025 · HL · contact PI
Resue of CF phagocyte function with CFTR modulator therapy$503,459
R01 · FY2025 · HL · contact PI
Resue of CF phagocyte function with CFTR modulator therapy$493,389
R01 · FY2024 · HL · contact PI
The role of CFTR during macrophage-mediated killing of bacteria$356,024
R01 · FY2024 · HL · contact PI
SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity$236,634
R21 · FY2024 · AI · contact PI
Resue of CF phagocyte function with CFTR modulator therapy$531,709
R01 · FY2023 · HL · contact PI
The role of CFTR during macrophage-mediated killing of bacteria$381,277
R01 · FY2023 · HL · contact PI
SMILE: Sickle Cell Disease Microbiologic and Immunologic Links to Health Equity$222,445
R21 · FY2023 · AI · contact PI
Rescue of CF phagocyte function with CFTR modulator therapy$611,287
R01 · FY2022 · HL · contact PI
The role of CFTR during macrophage-mediated killing of bacteria$384,785
R01 · FY2022 · HL · contact PI
The role of CFTR during macrophage-mediated killing of bacteria$387,928
R01 · FY2021 · HL · contact PI
The role of CFTR during macrophage-mediated killing of bacteria$394,642
R01 · FY2020 · HL · contact PI
Burkholderia-mediated defective killing mechanisms in macrophages from cystic fibrosis (CF) patients$176,504
K08 · FY2019 · AI · contact PI
Burkholderia-mediated defective killing mechanisms in macrophages from cystic fibrosis (CF) patients$176,504
K08 · FY2018 · AI · contact PI
Burkholderia-mediated defective killing mechanisms in macrophages from cystic fibrosis (CF) patients$176,504
K08 · FY2017 · AI · contact PI
Burkholderia-mediated defective killing mechanisms in macrophages from cystic fibrosis (CF) patients$151,200
K08 · FY2016 · AI · contact PI
Burkholderia-mediated defective killing mechanisms in macrophages from cystic fibrosis (CF) patients$150,912
K08 · FY2015 · AI · contact PI